Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in ne...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leuk Lymphoma
Hlavní autoři: Manasanch, Elisabet E., de Larrea, Carlos Fernández, Zingone, Adriana, Steinberg, Seth M., Kwok, Mary, Tageja, Nishant, Bhutani, Manisha, Kazandjian, Dickran, Roschewski, Mark, Wu, Peter, Carter, George, Zuchlinski, Diamond, Mulquin, Marcia, Lamping, Liz, Costello, Rene, Burton, Deborah, Gil, Lindsay A., Figg, William D., Maric, Irina, Calvo, Katherine R., Yuan, Constance, Stetler-Stevenson, Maryalice, Korde, Neha, Landgren, Ola
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357961/
https://ncbi.nlm.nih.gov/pubmed/27687480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1214953
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky